Clinical Trial 24120

• Overview

  Study Title:

  A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC).

• Treatments

  Therapies:

  Alkylating chemotherapy agent; Antibody-Drug Conjugate; Topoisomerase I inhibitor

  Medications:

  ABBV-706 (); PM01183 (lurbinectedin); Topotecan (); lurbinectedin ()

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.